arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Pasithea Therapeutics Corp.

KTTA

$0.52 ▼ -0.01 (-1.90%) at close

6 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Pasithea Therapeutics Corp. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.7M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -29.8% ↗

FCF / Share $-2.16 ↗

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$486.56K

↑ +3130.4% —

Net Income Profit after all expenses

$-20.43M

↓ -46.9% —

FCF / Share Free cash flow per share

$-2.16

↑ +83.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	—	—	—	3130.4% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+39030%)	—	—
EPS Growth YoY (%)	77.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-2921.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	23.6% Good Good Year-over-year change in earnings per share Optimal: > 10%	-161.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-46.9% Weak ↑ Weak Improving Year-over-year change in net income	12.9% Fair ↑ Fair Improving Year-over-year change in net income	-14.5% Weak Weak Year-over-year change in net income	-541.2% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	83.0% Excellent Excellent Year-over-year change in free cash flow	—	—	-92.6% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
FCF / Net Income (x)	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.00x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	—	1.07x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	1.47x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-29.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-76.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-54.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-27.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-6.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-34.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-88.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-61.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-8.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-37.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-347%)	-94.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-727%)	-68.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-555%)	-32.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-319%)	-4.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-128%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	-1578.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-145258.05x Weak Weak Operating income divided by interest expense Optimal: > 5x	-8872.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-55.16M	$-6.92M	$-16.33M	$-33.15M	$-52.97M	$-243.65K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	—	—	—	$0.02	$0.00	—
Basic EPS, GAAP (USD)	$-2.91	$-12.69	$-0.42	$-0.55	$-0.21	—
Free Cash Flow per Share (USD)	$-2.16	$-12.70	—	$-0.59	$-0.31	—
Book Value per Share (USD)	$2.39	$10.60	$22.46	$1.63	$2.23	$0.03
Tangible Book Value per Share (USD)	$2.27	$9.70	$13.63	$1.25	$2.23	$0.03
Basic Weighted Avg Shares (shares)	7.03M	1.10M	1.23M	25.25M	10.40M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$51.49M	$6.25M	$14.06M	$32.20M	$52.85M	$241.35K
Total Equity (USD)	$55.22M	$14.78M	$23.40M	$42.50M	$51.42M	$241.35K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$486.56K	$15.06K	—
Depreciation Expense (USD)	$32.42K	$18.86K	$18.29K	$31.52K	$1.38K	—
Net Income, GAAP (USD)	$-20.43M	$-13.90M	$-15.96M	$-13.94M	$-2.17M	—
Operating Cash Flow (USD)	$-15.21M	$-13.92M	—	$-14.56M	$-3.17M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 24 quarters

Pasithea Therapeutics Corp.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare KTTA with peers